|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||1.40 - 1.64|
|52-week range||1.40 - 1.64|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
SAN DIEGO, Jan. 17, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ:ARCT), a leading RNA medicines company, announced today that it is extending its partnership with Takeda Pharmaceutical Company Limited (TSE:4502) (Takeda).
On a per-share basis, the Tel Aviv, Israel-based company said it had a loss of 9 cents. The company's shares closed at $1.35. A year ago, they were trading at $1.91. _____ This story was generated by Automated ...
The U.S. Food and Drug Administration on Tuesday approved Shire Plc's long-acting therapy for attention deficit hyperactivity disorder , adding another treatment to its stock of drugs for the cognitive ...